Dr. G. Sridhar Prasad is the cofounder and CEO of EyeVision Pharma. He also serves as board of directors of Drugs Made in America Acquisition Corp. (NASDAQ: DMAA) . Dr. Prasad led crystallography efforts that at Takeda (formerly Syrrx) for the discovery of Nesina®, a T2D drug. At Merck he was lead crystallographer for drug discovery programs of schizophrenia, oncology and HIV-1 AIDS. Dr. Prasad co-founded Plex Pharmaceuticals in 2009, which was acquired by Collidion, Inc. in 2017, and served as its Chief Scientific Officer from 2009 to 2022. Prior to founding Nnavata, he was the Director and Head of Protein Science at Ventus Therapeutics, Waltham, MA, a clinical-stage biopharmaceutical company deploying leading-edge structural biology and unique computational chemistry tools to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology. Dr. Prasad has raised ~$10 million in non-dilutive funding from NIH and Michael J Fox Foundation for Parkinson’s Research. Dr. Prasad is co-inventor on thirteen U.S./ International issued patents and published 45 peer-reviewed research articles and textbook chapters.Dr. Prasad received his Ph.D. in Biophysics from the Indian Institute of Science, Bangalore, and postdoctoral training at the University of Minnesota and the Scripps Research Institute, La Jolla, California.